Reliability of Japanese clinical trials estimated from GCP audit findings

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 8, 2008, Pages 415-420

  Saito, K ^a   Kodama, Y ^b   Ono, S ^c   Maida, C ^a   Fujimura, A ^d   Miyamoto, E ^a  

^a HOKURIKU UNIVERSITY   (Japan)

^b JOSAI INTERNATIONAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Good Clinical Practice research environment; Japanese clinical trials

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; CLINICAL RESEARCH; DRUG RESEARCH; GOOD CLINICAL PRACTICE; JAPAN; MEDICAL AUDIT; PRIVATE HOSPITAL; PROFESSIONAL STANDARDS REVIEW ORGANIZATION; PUBLIC HOSPITAL; RELIABILITY; UNIVERSITY HOSPITAL;

EID: 48749105647     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46415     Document Type: Article

References (14)

1. Akiyama T. Current status of GCP audit (Japanese). In: Japanese Pharmacist Training Center. The workshop of clinical trials and compliance review from April 2004 to March 2005. Tokyo: Japanese Pharmacist Training Center; 2005. p. 77-90.
2. International Conference on Harmonization (ICH). Harmonized Tripartite Guidelines (Step 4), Guideline for good clinical practice. Geneva: ICH secretariat; 1996.
3. Kusuoka H. Present status of CRC in Japan: a survey towards the globalization of clinical trial - international symposium on clinical research of new drugs. In: International Symposium on Clinical Research secretariat (ed). Record of International Symposium on Clinical Research. Tokyo: MIX, Elsevier; 2001. p. 28-41.
4. Ministry of Health, Labor and Welfare. Guideline for good clinical practice. Pharmaceutical Affairs Bureau Notification No. 874. Tokyo: Ministry of Health, Labor and Welfare; 1989.
5. Ministry of Health, Labor and Welfare. MHLW Ordinance. 1997; 28.
6. Ministry of Health, Labor and Welfare. MHLW Ordinance. 2006; 72.
7. Ono S, Kodama Y, Nagao T, Toyoshima S. The quality of conduct in Japanese clinical trials: deficiencies found in GCP inspections. Contr Clin Trials. 2002; 23: 29-41.
8. Saito K, Kodama Y, Ono S, Fujimura A. Recent changes in quality in Japanese clinical trials. Ann Pharmacother. 2004; 38: 151-155.
9. Saito K, Kodama Y, Ono S, Mutoh M, Kawashima S, Fujimura A. Current status of quality in Japanese clinical trials. Contem Clin Trials. 2005; 26: 503-509.
10. Saito K, Kodama Y, Ono S, Mutoh M, Kawashima S, Fujimura A. Quality of Japanese clinical trials estimated from GCP audit findings. Am J Ther. 2006a; 13: 127-133.
11. Saito K, Kodama Y, Ono S, Maida C, Mutoh M, Miyamoto E. Estimation of the quality of clinical trials from GCP audit findings in Japan. Int J Pharm Med. 2006b; 20: 115-119.
12. Shimatani K. What is driving cost in clinical trials - how can we contain cost? In: Takeuchi M, Lagakos SW (eds). Global development strategies of new drugs. The 5th Kitasato University-Harvard School of Public Health Symposium. Tokyo: Rinsho-Hyoka-kannko-kai; 2005. p. 87-99.
13. Shimatani K. Clinical trial performance and cost survey. In: Takeuchi M, Lagakos SW (eds). The 7th Kitasato University-Harvard School of Public Health Symposium. Tokyo: Rinsho-Hyoka-kannko-kai; 2007. p. 139-154.
14. Uno H. A survey of investigator's motivation to conducting clinical trials. In: Takeuchi M, Lagakos SW (eds). The 7th Kitasato University-Harvard School of Public Health Symposium, Program and Abstract; 2006. p. 31-32.